Institute For In Vitro Sciences Inc is located in Gaithersburg, MD. The organization was established in 1997. According to its NTEE Classification (B28) the organization is classified as: Special Education, under the broad grouping of Education and related organizations. As of 12/2023, Institute For In Vitro Sciences Inc employed 54 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Institute For In Vitro Sciences Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Institute For In Vitro Sciences Inc generated $6.9m in total revenue. This represents relatively stable growth, over the past 9 years the organization has increased revenue by an average of 6.3% each year. All expenses for the organization totaled $7.2m during the year ending 12/2023. While expenses have increased by 6.1% per year over the past 9 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
TO INCREASE THE USE AND ACCEPTANCE OF NON-ANIMAL TEST METHODS WORLDWIDE.
Describe the Organization's Program Activity:
Part 3 - Line 4a
SCIENCE PROGRAM:IIVS WORKED WITH MORE THAN SIXTY COMPANIES TO DETERMINE THE APPROPRIATE NON-ANIMAL TESTING STRATEGIES, CONDUCT TESTING, AND ASSISTS IN INTERPRETATION OF DATA. OVER 880 COMPOUNDS/PRODUCTS WERE TESTED AT THE IIVS LABORATORY - MOST IN MORE THAN ONE TEST. IIVS CONTINUES TO OPTIMIZE AND STANDARDIZE IN VITRO METHODS TO MAKE THEM SUITABLE FOR INDUSTRY AND REGULATORY NEEDS. MANY OF THESE EFFORTS ARE IN COLLABORATION WITH STAKEHOLDERS SUCH AS INDUSTRY, GOVERNMENT AND NGOS. ADVANCEMENTS ARE SHARED WITH THE SCIENTIFIC COMMUNITY THROUGH PRESENTATIONS AND PUBLICATIONS SO THAT OTHER INDUSTRY AND REGULATORY SCIENTISTS CAN BENEFIT. IIVS HAS DEVELOPED AND PROMOTED THE USE OF HUMAN PRECISION CUT LUNG SLICES (HPCLS) FOR POTENTIAL REGULATORY APPLICATION AS AN ALTERNATIVE TO USING ANIMALS FOR INHALATION AND RESPIRATORY ENDPOINTS. BASED UPON OUR SUCCESSFUL USE OF HPCLS IN IN-HOUSE STUDIES, STAKEHOLDERS HAVE INQUIRED WHETHER THEY COULD PROCURE THESE HPCLS TISSUES FOR USE WITHIN THEIR OWN LABORATORIES. IIVS PREPARED AND QUALIFIED HPCLS TISSUES FOR 17 SPONSOR RUN LABORATORY STUDIES THAT WOULD HAVE OTHERWISE USED ANIMALS.
EDUCATION AND OUTREACH PROGRAM:IIVS PARTICIPATES IN NUMEROUS TRAINING ACTIVITIES FOR A VARIETY OF STAKEHOLDERS INCLUDING INDUSTRY AND REGULATORY SCIENTISTS. THESE TRAININGS ARE TAILORED FOR THE SPECIFIC AUDIENCE AND GENERALLY INCLUDE LECTURES, HANDS-ON DEMONSTRATIONS AND DATA INTERPRETATION. TWO MAJOR PROGRAMS IN WHICH IIVS PARTICIPATES ARE THE PHYSICIANS COMMITTEE FOR RESPONSIBLE MEDICINE NURA TRAINING AND THE ANIMAL FREE SAFETY ASSESSMENT COLLABORATION COORDINATED BY HUMANE SOCIETY INTERNATIONAL. IIVS SCIENTISTS WERE INVITED TO PARTICIPATE IN EXPERT PANELS CONVENED BY THE ORGANIZATION FOR ECONOMIC COOPERATION AND DEVELOPMENT (OECD) WHICH HARMONIZES IN VITRO TESTING APPROACHES FOR THE WORLDWIDE SCIENTIFIC COMMUNITY. THESE PANELS DISCUSSED NEW METHODS FOR GENETIC TOXICOLOGY, SKIN SENSITIZATION, EYE IRRITATION AND SKIN CORROSION. IIVS IS LEADING EFFORTS WITH INDUSTRY CONSORTIA AND 2 DIVISIONS OF THE US FEDERAL DRUG ADMINISTRATION TO APPLY NON-ANIMAL METHODS FOR SPECIFIC ENDPOINTS. IIVS IS ALSO INVOLVED IN EFFORTS TO SUPPORT THE US ENVIRONMENTAL PROTECTION AGENCY'S GOAL TO REDUCE RELIANCE ON ANIMAL MODELS. IIVS STAFF HOLD BOARD POSITIONS WITHIN SOCIETIES THAT HAVE THE MISSION TO WORK COLLABORATIVELY TO INCREASE THE USE AND ACCEPTANCE OF ALTERNATIVE METHODS, SUCH AS THE AMERICAN SOCIETY FOR CELLULAR AND COMPUTATIONAL TOXICOLOGY, THE EUROPEAN SOCIETY FOR TOXICOLOGY IN VITRO, THE US SOCIETY OF TOXICOLOGY AND THE CHINESE SOCIETY OF TOXICOLOGY.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
John R Fowle Director | Trustee | 0.5 | $0 |
James M Hoffman Director | Trustee | 0.5 | $0 |
Richard E Kouri Director | Trustee | 0.5 | $0 |
A Wallace Hayes Director | Trustee | 0.5 | $0 |
Daniel A Bagley Director | Trustee | 0.5 | $0 |
Rodger D Curren Ceo/board Chair/secretary | OfficerTrustee | 10 | $51,077 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $0 |
Government grants | $16,438 |
All other contributions, gifts, grants, and similar amounts not included above | $1,041,164 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $1,057,602 |
Total Program Service Revenue | $5,815,193 |
Investment income | $5,609 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | -$488 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $6,877,981 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $0 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $386,268 |
Compensation of current officers, directors, key employees. | $125,515 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $2,857,774 |
Pension plan accruals and contributions | $85,453 |
Other employee benefits | $877,618 |
Payroll taxes | $296,052 |
Fees for services: Management | $0 |
Fees for services: Legal | $11,013 |
Fees for services: Accounting | $97,909 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $80,160 |
Advertising and promotion | $26,041 |
Office expenses | $56,052 |
Information technology | $186,200 |
Royalties | $5,091 |
Occupancy | $477,820 |
Travel | $116,390 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $21,306 |
Interest | $9,659 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $223,023 |
Insurance | $80,306 |
All other expenses | $0 |
Total functional expenses | $7,165,636 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $11,393 |
Savings and temporary cash investments | $543,171 |
Pledges and grants receivable | $50,003 |
Accounts receivable, net | $1,701,761 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $124,103 |
Net Land, buildings, and equipment | $1,050,597 |
Investments—publicly traded securities | $0 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $2,671,824 |
Total assets | $6,152,852 |
Accounts payable and accrued expenses | $446,846 |
Grants payable | $0 |
Deferred revenue | $207,001 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $95,253 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $3,061,865 |
Total liabilities | $3,810,965 |
Net assets without donor restrictions | $2,306,887 |
Net assets with donor restrictions | $35,000 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $6,152,852 |